CD109 is a potential target for triple-negative breast cancer

• DOI: 10.1007/s13277-014-2509-5
• Publication Date: 2014-08-22T11:08:31Z
• Authors: Ji Tao; Hongbin Li; Qingwei Li; Yu Yang
• Keywords: Triple-negative breast cancer; CD24

The aim of this study is to explore the expression CD109 in breast cancer stem cells and relationship between protein clinicopathological characteristics cancer. CD44+/CD24− tumor (CSCs) were selected by flow cytometry. was analyzed immunohistochemistry staining, parameters determined. positively regulated proliferation CSCs vitro, significantly higher triple-negative (TNBC) compared non-TNBC (63.78 vs. 3.71 %, P = 0.001). Moreover, related histological grade (P 0.015), whereas age 0.731), size 0.995), clinical stage 0.644), lymph node metastasis 0.924) not. In logistic regression model, 0.001) molecular type expression. patients with high had poorer postoperative disease-specific survival than those no or low Cox regression, an independent prognostic factor highly expressed TNBC a potential biomarker for initiation, progression, differentiation tumors.